Conference App Sponsor: Pfizer Injectables
View analytic
Tuesday, July 31 • 2:30pm - 3:30pm
Clostridium difficile: A Review and Update to the 2010 Guidelines

Sign up or log in to save this to your schedule and see who's attending!

Download Presentation

  Abstract:  C. difficile is the most common cause of health-care associated diarrhea and as virulence increases, treatment failures become more common. Simple measures to improve prevention of C. difficile are the cornerstone of institutional management. Inadequate diagnosis of C. difficile-associated diarrhea may delay appropriate treatment and pathways that assist the prescriber with medication decisions. The IDSA released guidelines in 2010 to address many of these issues. However, a new antimicrobial, fidaxomicin, was approved for treatment of C. difficile-associated diarrhea, and clinical trials were published after the IDSA review. Fidaxomicin has been shown to reduce relapse relative to vancomycin, but at approximately $280 per day, fidaxomicin’s place in therapy is difficult to determine.

Learning Objectives:
     1.    Describe the morbidity and mortality associated with CDAD.
     2.    Discuss CDAD laboratory testing.
     3.    Describe current CDAD treatment options.


1 contact hour: P                                                                                  0262-9999-12-014-L04-P (K)


Josh Davis, PharmD, BCPS

Josh Davis, PharmD, BCPS, served as a critical care and infectious disease clinical pharmacist at Gadsden Regional Medical Center. He currently serves as the director of clinical pharmacy research at CHS.

Tuesday July 31, 2012 2:30pm - 3:30pm
Room 114

Attendees (0)